96 results
8-K
EX-99.1
MAIA
MAIA Biotechnology Inc
6 Jun 24
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
2:57pm
survival (PFS) of 5.5 months
median survival follow-up time of 9.1 months
THIO works well in all doses and has an excellent safety profile, but 180mg has … . The trial design has two primary objectives: (1) to evaluate the safety and tolerability of THIO administered as an anticancer compound and a priming
8-K
EX-99.3
MAIA
MAIA Biotechnology Inc
4 Jun 24
Regulation FD Disclosure
4:06pm
trial are to examine the safety and tolerability of THIO as an anticancer drug and as an immune system primer, and to examine the clinical efficacy … the safety and tolerability of THIO administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of THIO using
8-K
EX-99.1
MAIA
MAIA Biotechnology Inc
4 Jun 24
Regulation FD Disclosure
4:06pm
: MAIA A Multicenter, Open-Label, Dose-Finding Phase 2 Trial Evaluating the Safety and Efficacy of THIO Administered in Sequence with LIBTAYO® … (cemiplimab) in NSCLC patients RESISTANT TO CHECKPOINT INHIBITORS Part A: Part B: Expansion: 1 Safety Efficacy / Safety / Dose Selection Registration Every 3
8-K
EX-99.1
MAIA
MAIA Biotechnology Inc
3 Jun 24
Regulation FD Disclosure
4:05pm
chemotherapy. Introduction Methods Using a modified 3+3 design, the safety lead-in (Part A) enrolled 10 patients who received THIO 360 mg IV (120 mg QD … % of patients had ≥2 prior treatment lines at study entry. Safety findings THIO + cemiplimab has so far been well tolerated in a heavily pre-treated
8-K
EX-99.2
MAIA
MAIA Biotechnology Inc
3 Jun 24
Regulation FD Disclosure
4:05pm
2015 Jan;5(1):82-95. Mender I, et al. Cancer Cell 2020;38:400–11.
Methods Using a modified 3+3 design, the safety lead-in (Part A) enrolled 10 patients … of the treatment. An expansion cohort is planned based on data from Part B (n=100).
THIO-101 Study Schema THIO 60 mg ORR, DCR, Safety Best dose selected Nov 23
8-K
EX-10.1
z5hsp4rukfrvc0wu3
23 Apr 24
MAIA Biotechnology Announces $1.00 Million Private Placement
4:05pm
8-K
EX-10.1
ef70o 6z0e0ss4
26 Mar 24
MAIA Biotechnology Announces $1.33 Million Private Placement
3:36pm
8-K
EX-10.1
s5e14fgxuw
13 Mar 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-99.1
6bhuo5r fh
8 Mar 24
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
4:15pm
8-K
EX-99.2
1ywdz
8 Mar 24
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
4:15pm
8-K
EX-99.1
o118tvyz
6 Mar 24
Other Events
8:00am
8-K
EX-99.1
sk3ys
23 Feb 24
MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
4:17pm
424B5
e9jtl
14 Feb 24
Prospectus supplement for primary offering
5:18pm
8-K
EX-1.1
yhp9a trpl0
14 Feb 24
Entry into a Material Definitive Agreement
5:15pm
8-K
EX-99.1
0sb4n7ib
18 Jan 24
MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024
6:01am
8-K
fhn kg72dhiskce
21 Dec 23
MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
7:00am
8-K
EX-99.1
m52by9
21 Dec 23
MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
7:00am
8-K
EX-10.1
q7anw2v
17 Nov 23
MAIA Biotechnology Announces $4 Million Registered Direct Offering
9:09am